{"id":4568,"date":"2024-06-14T09:14:34","date_gmt":"2024-06-13T23:14:34","guid":{"rendered":"\/eu-uk\/?p=4568"},"modified":"2024-06-28T12:04:37","modified_gmt":"2024-06-28T02:04:37","slug":"petra-capital-research-report-june-2024","status":"publish","type":"post","link":"\/eu-uk\/blog\/2024\/06\/14\/petra-capital-research-report-june-2024\/","title":{"rendered":"Petra Capital Research Report | June 2024"},"content":{"rendered":"<p>Petra Capital has released research report, forecasting Orthocell\u2019s potential to reach A$1.28 per share.<\/p>\n<p>Following last week\u2019s <a href=\"https:\/\/url.avanan.click\/v2\/___https:\/announcements.asx.com.au\/asxpdf\/20240611\/pdf\/064fyw4krr1qw3.pdf___.YXAzOm9ydGhvY2VsbDphOm86NzNkZjFjYTYyZTQ0OTNhYTBlNDE5ZWYyOTE1MjhlNTc6NjpjMzc1OmZlZTRiMmQyZDZjNzU1N2Q3NmZmYTJlYTIxN2IzNDNmMDM0MGExNTYxY2QzN2ZjM2VjMWNmOGQzYzZmZThkY2I6cDpU\">announcement that Orthocell has applied to the TGA for Australian market approval for its SmrtGraft\u2122 tendon repair device<\/a>, the report forecasts Orthocell\u2019s potential to reach A$1.28 per share.<\/p>\n<p><em>\u201cOCC\u2019s SmrtGraft\u2122 tendon product application for approval in Australia opens up a potential third product revenue stream for the CelGro\u2122 platform and is currently not in our forecasts. For use by Orthopaedic surgeons, we see distribution as well as manufacturing synergies with OCC\u2019s Remplir nerve product. As such, it represents a potential attractive revenue stream without much additional cost. With OCC on track for US approval of Remplir in 1QCY25, our TP of $1.28\/sh offers &gt;3x upside.\u201d <\/em><\/p>\n<p><a href=\"https:\/\/url.avanan.click\/v2\/___https:\/bit.ly\/OCC-Petra-Capital___.YXAzOm9ydGhvY2VsbDphOm86NzNkZjFjYTYyZTQ0OTNhYTBlNDE5ZWYyOTE1MjhlNTc6NjpkZmE5OjBkMmU1NDM1MDA5NjQ3Yzc0MThiNGEyMWQxNGY0NzkyYTJmOWMzODBhOWIyZGEyNmU0MmJkYWQyNjFmNTFkMzA6cDpU\">Click here to read the research report. <\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Petra Capital has released a research report, forecasting Orthocell\u2019s potential to reach A$1.28 per share.<\/p>\n","protected":false},"author":2,"featured_media":4577,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2,3],"tags":[],"class_list":["post-4568","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news","category-media"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4568"}],"version-history":[{"count":3,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4568\/revisions"}],"predecessor-version":[{"id":4579,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4568\/revisions\/4579"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4577"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4568"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}